Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/ Phase 2, 12-week, multi-center, randomized, double-blind, cross-over,
placebo-controlled study to evaluate the efficacy and safety of ELS-M11 compared to placebo
in 50 male and female subjects, aged 18 to 65 years that suffer recurring moderate-severe
migraine headaches (2-8 per month).
This study is designed to describe the efficacy and safety of ELS-M11 as compared to placebo.